Search Results | Litt's Drug Eruption and Reaction Database

Adverse reactions attributed to entire drug class 'Immune checkpoint inhibitor (incl. programmed death receptor-1 (PD-1) inhibitor)'

Please login to view adverse reactions.

Bullous pemphigoid / pemphigoid

(2024): Li JH+, Zhongguo Yi Xue Ke Xue Yuan Xue Bao 46(6), 872-882 (32 cases)
(2022): Bur D+, J Am Acad Dermatol Aug, Online ahead of print (20 cases)
(2022): Ingen-Housz-Oro S+, Melanoma Res Mar, Online ahead of print
(2022): Schauer F+, Front Immunol Jul (e-Collection) (8 cases)
(2021): Ogawa K+, Clin Drug Investig Jun, Online ahead of print [REVIEW]
(2020): Molina GE+, Br J Dermatol Jun, Online ahead of print (15 cases)
(2020): Morris LM+, J Cutan Pathol Mar, Epub ahead of print (2 cases)
(2019): Fontecilla NM+, J Drugs Dermatol 18(1), 103 (1 case)
(2019): Kosche C+, Dermatol Online J 25(10) (e-Collection) (1 case)
(2019): Sadik CD+, Front Immunol 10, 1934 (1 case)
(2018): Lopez AT+, Int J Dermatol Apr, Epub ahead of print [REVIEW]
(2017): Bandino JP+, J Eur Acad Dermatol Venereol 31(8), e378
(2016): Jour G+, J Cutan Pathol 43(8), 688 (5 cases)
(2016): Naidoo J+, Cancer Immunol Res 4(5), 383 (3 cases)

Cutaneous adverse reaction (includes severe cutaneous adverse drug reaction (SCAR))

(2023): L'Orphelin J-M+, J Eur Acad Dermatol Venereol Apr, Online ahead of print
(2023): Martel J+, Hum Pathol May, Online ahead of print [REVIEW]
(2023): Medri M+, Ital J Dermatol Venerol 158(6), 437-444
(2022): Chen CH+, Curr Oncol 29(4), 2871-2886 [REVIEW]
(2022): Juan-Carpena G+, Actas Dermosifiliogr 113(4), 376-387 [REVIEW]
(2022): Salloum A+, Immunotherapy 14(6), 489-503 [REVIEW]

Cutaneous eruptions

(2020): Inoue S+, Gan To Kagaku Ryoho (Japanese) 47(8), 1189-1192 (9 cases)

Cutaneous toxicity / skin toxicity

(2022): Nikolaou V+, Br J Dermatol Jul, Online ahead of print
(2022): Yamamoto T, Clin Cosmet Investig Dermatol 15, 829-841 [REVIEW]
(2018): Sibaud V+, Ann Dermatol Venereol (French) Apr, Epub ahead of print [REVIEW]
(2018): Wang DY+, Cancer J 24(1), 36 [REVIEW]
(2016): Spain L+, Cancer Treat Rev 44, 51 [REVIEW]

DRESS syndrome (Drug-induced hypersensitivity syndrome)

(2023): Ingen-Housz-Oro S+, Melanoma Res Feb, Online ahead of print (13 cases)

Eczema / eczematous reaction / eczematous eruption

(2016): Hwang SJ+, J Am Acad Dermatol 74(3), 45517%

Granulomatous reaction

(2022): Taskaynatan H+, Melanoma Res Jun, Online ahead of print (3 cases)

Keratoacanthoma (Grzybowski syndrome)

(2025): Mager L+, Arch Dermatol Res 317(1), 234 (19 cases) [REVIEW]
(2017): Bandino JP+, J Eur Acad Dermatol Venereol 31(8), e378

Lichen planus (includes hypertrophic lichen planus)

(2024): Meier-Schiesser B+, JAAD Int 15, 157-164
(2022): Alharbi A+, Int J Environ Res Public Health 20(1), 580 [REVIEW]
(2016): Wakade DV+, Melanoma Res 26(4), 421 (3 cases)

Lichen sclerosus

(2022): Alharbi A+, Int J Environ Res Public Health 20(1), 580 [REVIEW]

Lichenoid eruption / lichenoid reaction

(2020): Sethi M+, Dermatol Online J 26(12) (2 cases / female) (diagnosed as an inverse variant of lichenoid eruption)
(2016): Hwang SJ+, J Am Acad Dermatol 74(3), 45517%

Lipodystrophy / acquired generalised lipodystrophy

(2025): Riganti J+, JAMA Dermatol Apr, Online ahead of print

Lupus erythematosus (subacute cutaneous lupus erythematosus (SCLE))

(2024): Wu Z+, Arch Dermatol Res 316(10), 722 (29 cases)

Pruritus (itching)

(2017): Gauci ML+, Cancer Immunol Immunother 66(11), 1399 [REVIEW]

Psoriasis

(2024): Pach JJ+, Dermatol Clin 42(3), 481-493 [REVIEW]
(2023): Mebarki S+, Bull Cancer Mar, Online ahead of print2%
(2021): Halle BR+, J Immunother Cancer 9(10), e00306657% (exacerbation)
(2016): Chia PL+, J Immunother 39(5), 202 (flare)

Rash

(2023): Mebarki S+, Bull Cancer Mar, Online ahead of print14%
(2019): Zhou H+, Front Pharmacol 10, e38715% (3% ≥ grade 3) [REVIEW]
(2017): Gauci ML+, Cancer Immunol Immunother 66(11), 1399 [REVIEW]

Raynaud's phenomenon

(2020): Khan S+, Oncologist Mar, Epub ahead of print (1 case) (with anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) therapy)

Sarcoidosis / sarcoid-like reaction (cutaneous sarcoidosis)

(2020): Chorti E+, Eur J Cancer 131, 18 (10 cases) (drug-induced sarcoidosis-like reaction)
(2019): Cohen Aubart F+, J Intern Med Oct, Epub ahead of print [REVIEW]

Scleroderma

(2023): Nicoletti MM+, Drugs Real World Outcomes Oct, Online ahead of print (70 reports)
(2020): Terrier B+, Autoimmun Rev Aug (e-Collection)

Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN)

(2025): Zheng Z+, Oncologist 30(6), oyaf143 (110 cases) [REVIEW]
(2024): Qin K+, J Inflamm Res 17, 7591-7605 [REVIEW]
(2023): Satoh TK+, J Dermatol Nov, Online ahead of print [REVIEW]
(2021): Zhu J+, EClinicalMedicine Jul (e-Collection) [REVIEW] (association)
(2016): Goldinger SM+, Clin Cancer Res 22(16), 4023

Vasculitis (angiitis) / cutaneous vasculitis (angiitis)

(2020): Kullberg SA+, Dermatol Online J 26(9) (e-Collection) (1 case / male)
(2018): Daxini A+, Clin Rheumatol 37(9), 2579-2584 [REVIEW]

Vitiligo

(2023): Lo J+, Arch Dermatol Res Feb, Online ahead of print (151 cases)
(2021): Lommerts JE+, Expert Opin Drug Saf Apr, Online ahead of print [REVIEW]
(2019): Babai S+, Drug Saf Oct, Epub ahead of print [REVIEW]
(2017): Gauci ML+, Cancer Immunol Immunother 66(11), 1399 [REVIEW]
(2016): Hwang SJ+, J Am Acad Dermatol 74(3), 45515%

Alopecia areata

(2020): Antoury L+, Dermatol Ther 33(6), e14171 (13 cases) [REVIEW]

Hair pigmentation

(2017): Rivera N+, JAMA Dermatol 153(11), 1162 (re-pigmentation)

Onycholysis

(2023): Mebarki S+, Bull Cancer Mar, Online ahead of print2%

Oral changes

(2017): Vigarios E+, Support Care Cancer 25(5), 1713 [REVIEW]

Oral mucosal reactions

(2023): Vigarios E+, Ann Dermatol Venereol Mar, Online ahead of print [REVIEW]

Sicca syndrome / sicca symptoms (see also Sjögren‘s syndrome)

(2024): Bitoun S+, Rheum Dis Clin North Am 50(2), 291-300 [REVIEW]
(2022): Harris JA+, Oral Dis 28(8), 2083-2092 [REVIEW]
(2020): Pringle S+, Clin Exp Rheumatol 38Suppl 126 (4), 253-260 [REVIEW]
(2019): Warner BM+, Oncologist 24(9), 1259-1269

Capillary leak syndrome

(2023): Wong So J+, J Intern Med 294(1), 58-68 (47 cases) [REVIEW] (association)
(2020): Umeda Y+, J Dermatol 47(11), 1322-1325

Cardiotoxicity

(2024): Wang Y+, Front Cardiovasc Med Jun (e-Collection) (51 cases)
(2024): Yamani N+, Cardiooncology 10(1), 37 [REVIEW]
(2023): Ho CC+, J Chin Med Assoc 86(5), 499-505
(2023): Li X+, Front Immunol Feb (e-Collection) [REVIEW]
(2022): Ganesh S+, Front Cardiovasc Med Sep (e-Collection) [REVIEW]
(2022): Zito C+, Cancers (Basel) 14(21), 5403 [REVIEW]
(2021): Arangalage D+, Cancer Treat Rev Aug, Online ahead of print [REVIEW]
(2021): Chen C+, Front Pharmacol Feb (e-Collection) [REVIEW]
(2021): Dolladille C+, Eur Heart J Sep, Online ahead of print [REVIEW]
(2018): Dong J+, Front Cardiovasc Med 5, 9 [REVIEW]

Cardiovascular adverse effect (includes major adverse cardiovascular events (MACE))

(2024): Eldani C+, Front Oncol Jul (e-Collection) (grade 3–4)
(2024): Nielsen DL+, JAMA Oncol Aug, Online ahead of print [REVIEW]
(2022): Wu S+, Front Cardiovasc Med Aug (e-Collection) [REVIEW]
(2021): Faron A+, Radiology Sep, Online ahead of print
(2020): Khunger A+, Curr Oncol Rep 22(7), 65 [REVIEW]

Large-vessel vasculitis (includes giant cell arteritis)

(2025): Cottu A+, Rheumatology (Oxford) Mar, Online ahead of print (27 cases)
(2024): Hysa E+, Autoimmun Rev Aug, Online ahead of print [REVIEW]
(2020): Henderson D+, BMJ Case Rep 13(5), e233496 (1 case)

Myocarditis

(2024): Tomsitz D+, Eur J Cancer Dec, Online ahead of print
(2023): Coustal C+, J Immunother Cancer 11(5), e004792 (29 cases)
(2023): Gao J+, J Leukoc Biol May, Online ahead of print (multiomics)
(2023): Moradi A+, Cureus 15(7), e42071 [REVIEW]
(2022): Cadour F+, Radiology Mar, Online ahead of print (41 cases)
(2022): Deharo F+, J Clin Med 11(19), 5611 (3 cases)
(2022): Longinow J+, Cancer Med Sep, Online ahead of print (11 cases) (with myasthenia gravis, myositis and myocarditis overlap syndrome)
(2022): Thuny F+, JACC CardioOncol 4(5), 624-628 [REVIEW]
(2022): Vasbinder A+, JACC CardioOncol 4(5), 689-700 [REVIEW]
(2021): Esposito R+, Biomolecules 11(6), 785 [REVIEW]
(2021): Matzen E+, Cardiooncology 7(1), 27 (87 cases) [REVIEW]
(2021): Thuny F+, JACC CardioOncol 3(1), 157-161 [REVIEW]
(2020): Balanescu DV+, Cardiovasc Pathol 47, 107211 (3 cases)
(2020): Cautela J+, J Immunother Cancer 8(2), e001887 [REVIEW]
(2018): Mahmood SS+, J Am Coll Cardiol 71(16), 1755 (35 cases)
(2018): Tajiri K+, Jpn J Clin Oncol 48(1), 7 [REVIEW]
(2017): Wang DY+, Curr Cardiol Rep 19(3), 21 [REVIEW]
(2016): Johnson DB+, N Engl J Med 375(18), 1749 (fatal / 2 cases)

Myocarditis, myositis and myasthenia gravis overlap syndrome (Triple-M Syndrome)

(2023): Longinow J+, Cancer Med 12(3), 2281-2289 (11 cases)
(2021): Lipe DN+, Am J Emerg Med 46, 51-55 (7 cases)
(2021): Pathak R+, Oncologist 26(12), 1052-1061 (60 cases) [REVIEW]

Takotsubo syndrome

(2023): Trontzas IP+, Cancers (Basel) 15(9), 2637 (17 cases) [REVIEW]
(2019): Ederhy S+, Eur J Heart Fail 21(7), 945-947 [REVIEW]

Thromboembolism

(2022): Alghamdi EA+, Saudi Pharm J 30(8), 1193-1199 (possible association)
(2022): Liu T+, Curr Pharm Des Sep, Online ahead of print [REVIEW]
(2022): McCrae KR+, Thromb Res 213(Suppl 1), S51-S57 [REVIEW]
(2022): Sheng IY+, Target Oncol 17(5), 563-5699%

Bell's palsy (facial palsy)

(2023): Zhu J+, Int Immunopharmacol Nov, Online ahead of print (association)

Cerebral pseudoprogression

(2021): Urban H+, Front Immunol Jan (e-Collection) (12 cases)

Demyelination

(2020): Oliveira MCB+, Front Neurol Dec (e-Collection) (23 cases) [REVIEW]

Encephalitis

(2022): Müller-Jensen L+, Eur J Cancer 175, 224-235 (30 cases)
(2022): Müller-Jensen L+, Data Brief Dec (e-Collection) (30 cases)
(2021): Velasco R+, JAMA Neurol Mar, Online ahead of print [REVIEW]
(2019): Fujiwara S+, Intern Med Jun, Epub ahead of print (2 cases)

Fever (pyrexia) (includes hyperpyrexia)

(2019): Zhou H+, Front Pharmacol 10, e38713% [REVIEW]

Guillain-Barré syndrome / acute inflammatory demyelinating polyradiculoneuropathy / acute motor axonal neuropathy

(2020): Haugh AM+, Expert Opin Drug Saf 19(4), 479-488 [REVIEW]
(2020): Okada K+, J Neurol Sep, Online ahead of print (36 cases) [REVIEW]
(2019): McNeill CJ+, BMJ Case Rep 12(8), e229443 (1 case)

Myelitis / myeloradiculitis

(2025): Li YX+, Invest New Drugs Jun, Online ahead of print [REVIEW]
(2023): Chatterton S+, Front Neurol Feb (e-Collection) (4 cases)

Neurological adverse effect / neurological deficit

(2024): Eldani C+, Front Oncol Jul (e-Collection) (grade 3–4)
(2024): Stavropoulou De Lorenzo S+, Biomedicines 12(6), 1319 [REVIEW]

Neurological adverse effect / neurological deficit

(2024): Müller-Jensen L+, Data Brief Apr (e-Collection)
(2022): Ruggiero R+, Front Oncol Mar (e-Collection)
(2021): Cheng K+, Clin Med Insights Oncol Nov (e-Collection) [REVIEW]
(2021): Mikami T+, J Neurooncol 152(1), 135-1447% [REVIEW]
(2021): Plaçais L+, Brain Commun 3(4), fcab220 (40 cases)
(2020): Haugh AM+, Expert Opin Drug Saf 19(4), 479-488 [REVIEW]
(2020): Shi J+, Thorac Cancer 11(2), 481-487 [REVIEW]
(2019): Möhn N+, J Clin Med 8(11)~1% [REVIEW]
(2019): Pan PC+, Curr Oncol Rep 21(12), 108 [REVIEW]
(2019): Sato K+, J Neurooncol 145(1), 1-9 [REVIEW]
(2019): Shi J+, Zhongguo Fei Ai Za Zhi (Chinese) 22(10), 633-638 [REVIEW]

Neurotoxicity

(2023): Müller-Jensen L+, Neuro Oncol Oct, Online ahead of print (34 cases) (associated with subgroup-specific immune cell dysregulation)
(2022): Villagrán-García M+, Neurol Sci Feb, Online ahead of print2–12% [REVIEW]
(2021): Duong SL+, J Neurooncol Jan, Online ahead of print (18 cases)

Paraneoplastic neurological syndromes

(2020): Mongay-Ochoa N+, J Neurol 267(7), 2154-2156 (2 cases) [REVIEW]
(2019): Gill A+, J Neuroimmunol 334, 576980 (3 cases) (association)
(2019): Vogrig A+, Neurol Neuroimmunol Neuroinflamm 6(6), e604 (6 cases) (induction / exacerbation)

Adrenal insufficiency (hypoadrenalism) / Addisonian crisis (includes Addison's disease)

(2023): Xiang J+, Transl Oncol Sep, Online ahead of print (20 cases)
(2022): Takayasu S+, Sci Rep 12(1), 12944%
(2021): Iglesias P+, Pituitary Mar, Online ahead of print [REVIEW]
(2021): Iglesias P+, Endocr Relat Cancer Oct, Online ahead of print

Adrenalitis

(2020): Shi Y+, Endocr Pract Dec, Online ahead of print (15 cases)

Adrenocorticotropic hormone (corticotropin; ACTH) deficiency

(2024): Yang L+, Clin Endocrinol (Oxf) May, Online ahead of print (12 cases)
(2021): Iglesias P+, Pituitary 24(4), 630-643 (60 cases) [REVIEW]

Aspartate aminotransferase (AST) increased

(2019): Chen C+, Oncoimmunology 8(5), e1581547 (≥ grade 3) [REVIEW]
(2019): Wang BC+, Cancer Med Aug, Epub ahead of print2% (≥ grade 3) [REVIEW]

Autoimmune Polyendocrine Syndrome Type 2

(2021): Zhao Z+, Cancer Immunol Immunother 70(6), 1527-1540 (23 cases) [REVIEW]
(2020): Shi Y+, J Clin Endocrinol Metab 105(12), dgaa553 [REVIEW]

Diabetes insipidus

(2022): Barnabei A+, Front Oncol Mar (e-Collection) [REVIEW]
(2022): Barnabei A+, Front Endocrinol (Lausanne) Mar (e-Collection) [REVIEW]

Diabetes mellitus

(2025): Zhan M+, Front Immunol Jan (e-Collection)
(2024): Angelousi A+, Diseases 12(2), 40 (4 cases) (with concomitant medication)
(2024): Chen J+, Endocrine Jul, Online ahead of print [REVIEW]
(2024): Kani ER+, Endocrine Sep, Online ahead of print [REVIEW]
(2024): Ruiz-Esteves KN+, JAMA Oncol Aug, Online ahead of print
(2023): Cho YK+, Diabetes Metab J Jul, Online ahead of print [REVIEW]
(2023): Liao D+, Int Immunopharmacol Jun, Online ahead of print [REVIEW]
(2023): Marsiglio J+, Front Immunol Aug (e-Collection) (18 cases) (+/- chemotherapy)
(2022): Liu J+, Transl Oncol Jul, Online ahead of print (171 cases) [REVIEW]
(2021): Fischer M+, Harefuah (Hebrew) 160(10), 657-662 (2 cases) [REVIEW]
(2021): Lo Preiato V+, Rev Endocr Metab Disord Jan, Online ahead of print [REVIEW]
(2021): Muniz TP+, Cancers (Basel) 14(1), 89 (34 cases)
(2021): Ogawa K+, Clin Drug Investig Jun, Online ahead of print [REVIEW]
(2020): Quandt Z+, Clin Exp Immunol 200(2), 131-140 [REVIEW]
(2020): Zhang R+, Chin Med J (Engl) Aug, Online ahead of print [REVIEW]
(2020): Zheng Z+, Diabetes Metab Res Rev Jun, e3366 [REVIEW]
(2019): Kotwal A+, BMJ Open Diabetes Res Care 7(1), e000591 [REVIEW]

Diabetic ketoacidosis

(2022): Zhang W+, Front Endocrinol (Lausanne) Jan (e-Collection) (9 cases) [REVIEW]

(2024): Ata F+, BMC Med 22(1), 58827%
(2024): Elshafie O+, Endocrinol Diabetes Metab 7(4), e0050528%
(2021): Deligiannis NG+, Medicina (B Aires) 81(2), 269-278 [REVIEW]
(2020): Shi Y+, J Clin Endocrinol Metab Sep, Online ahead of print (30 cases) [REVIEW] (autoimmune polyendocrine syndrome type 2)

Graves' disease

(2021): Peiffert M+, Cancers (Basel) 13(8), 1944 (5 cases) [REVIEW]
(2019): Brancatella A+, Eur Thyroid J 8(4), 192 (1 case)

Hyperglycemia (includes glucose increased)

(2022): Zhang W+, Front Endocrinol (Lausanne) Jan (e-Collection) (9 cases) [REVIEW] (hyperosmolar hyperglycemia)

Hypertransaminasemia (hepatic transaminitis) / elevated transaminases

(2021): Xu F+, Transl Lung Cancer Res 10(4), 1819-1828 (6 cases)
(2020): Pu D+, Medicine (Baltimore) 99(5), e190133–17% (grade 3 or 4) [REVIEW]
(2020): Yamamoto A+, J Cancer Res Clin Oncol Nov, Online ahead of print

Hypophysitis

(2024): van der Leij S+, Front Endocrinol (Lausanne) Jul (e-Collection) (67 cases)
(2023): Chen P+, J Clin Med 12(10), 3468 [REVIEW]
(2023): Esteves-Ferreira S+, J Cancer Res Clin Oncol Mar, Online ahead of print
(2023): Quandt Z+, J Endocr Soc Feb (e-Collection) [REVIEW]
(2022): Jessel S+, Front Oncol Mar (e-Collection)
(2020): du Payrat JA+, Bull Cancer (French) Mar, Epub ahead of print [REVIEW]
(2020): Khan S+, Oncologist Mar, Epub ahead of print (1 case) (with anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) therapy )
(2020): Kurokawa R+, AJNR Am J Neuroradiol Aug, Online ahead of print
(2019): Albarel F+, Eur J Endocrinol 181(3), R107 [REVIEW]
(2019): Di Dalmazi G+, Expert Rev Endocrinol Metab 14(6), 381 [REVIEW]
(2019): Thapi S+, J Immunother Cancer 7(1), 248 (1 case)
(2019): Wei KZ+, Melanoma Manag 6(1), eCollection MMT1312%
(2016): Spain L+, Cancer Treat Rev 44, 51 [REVIEW]

Hypopituitarism

(2024): Iwamoto Y+, Cureus 16(10), e71699
(2022): Yamada H+, BMC Endocr Disord 22(1), 110 (12 cases)
(2019): Chen C+, Oncoimmunology 8(5), e1581547 (≥ grade 3) [REVIEW]

Hypothyroidism

(2022): Phillips AL+, Ann Pharmacother Feb, Online ahead of print19%
(2020): Tian Z+, Cancer Manag Res 12, 133914% (with doxorubicin)
(2019): Zhou H+, Front Pharmacol 10, e38714% [REVIEW]

Pancreatic enzymes increased

(2024): Brandlmaier M+, J Eur Acad Dermatol Venereol Nov, Online ahead of print14%

Thyroid disorder

(2024): Karaviti D+, Endocrine Feb, Online ahead of print [REVIEW]
(2022): Patrizio A+, Curr Pharm Des May, Online ahead of print (10 cases)

Thyroid dysfunction

(2025): Shibutani Y+, J Immunother 48(5), 183-188
(2025): Wang A+, Endocrine Jan, Online ahead of print
(2025): Yamauchi I+, Eur Thyroid J Jan, Online ahead of print [REVIEW]
(2024): Wang Y+, Heliyon 10(5), e27077 [REVIEW]
(2023): Albarel F+, Ann Endocrinol (Paris) Mar, Online ahead of print [REVIEW]
(2022): Baek HS+, BMC Endocr Disord 22(1), 8934%
(2021): Zhou N+, Lung Cancer 161, 34-41
(2020): Pollack R+, J Clin Endocrinol Metab Jul, Online ahead of print39%
(2020): Zhou Y+, Int Immunopharmacol Dec, Online ahead of print
(2018): De Bruyne P+, Arch Dis Child 103(1), 78 (long-term use)
(2017): Chalan P+, J Endocrinol Invest Dec, Epub ahead of print [REVIEW]
(2016): Spain L+, Cancer Treat Rev 44, 51 [REVIEW]

Thyroiditis

(2021): Abraham G+, Int J Cancer Nov, Online ahead of print2%
(2017): Gauci ML+, Cancer Immunol Immunother 66(11), 1399 [REVIEW]

Thyrotoxicosis

(2023): Lee HJ+, Front Endocrinol (Lausanne) Apr (e-Collection) (124 cases)
(2021): Brancatella A+, J Endocr Soc 5(9), bvab093 (20 cases)

Abdominal pain

(2017): Collins M+, Ann Oncol 28(11), 2860

Celiac disease / coeliac disease

(2020): Badran YR+, J Immunother Cancer 8(1), e000958 (8 cases) (association)

Cholangitis / sclerosing cholangitis

(2021): Pi B+, Eur J Gastroenterol Hepatol Sep, Online ahead of print [REVIEW]
(2020): Fujii M+, Clin J Gastroenterol Sep, Online ahead of print (1 case / male) (with chemotherapy)

Cholestasis / cholestatic jaundice

(2025): Yan X+, Int J Surg Jun, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)

Colitis

(2025): Kim TK+, Korean J Intern Med 40(1), 49-564%
(2025): Pesch G+, Cancer Immunol Res Apr, Online ahead of print (pharmacogenomics)
(2025): Zaher A+, Expert Opin Drug Saf Apr, Online ahead of print [REVIEW]
(2024): Lenti MV+, ESMO Open Jul, Online ahead of print (96 cases)
(2024): Zoghbi M+, Support Care Cancer 32(10), 680 [REVIEW]
(2023): Desmedt V+, Eur J Cancer 187, 36-57 [REVIEW]
(2023): Losurdo G+, Biomedicines 11(5), 1496 [REVIEW]
(2023): Mebarki S+, Bull Cancer Mar, Online ahead of print5%
(2023): Nakane T+, Kurume Med J Apr, Online ahead of print [REVIEW]
(2023): Terrin M+, Int J Mol Sci 24(14), 11504 [REVIEW]
(2022): Vaziri H+, J Clin Gastroenterol Apr, Online ahead of print [REVIEW]
(2021): Farha N+, Clin Res Hepatol Gastroenterol Jul, Online ahead of print4%
(2021): Ogawa K+, Clin Drug Investig Jun, Online ahead of print [REVIEW]
(2021): Portenkirchner C+, Pharmaceuticals (Basel) 14(4), 367 [REVIEW]
(2021): Yanai S+, Digestion Sep, Online ahead of print [REVIEW]
(2020): Bellaguarda E+, Am J Gastroenterol Jan, Epub ahead of print [REVIEW]
(2019): Abu-Sbeih H+, Curr Opin Gastroenterol Oct, Epub ahead of print [REVIEW]
(2019): Chen C+, Oncoimmunology 8(5), e1581547 (≥ grade 3) [REVIEW]
(2019): Delasos L+, Case Rep Oncol Med Jul, 2019:9069354 (1 case)
(2019): Som A+, World J Clin Cases 7(4), 405 [REVIEW]
(2019): Yanai S+, Dig Endosc Oct, Epub ahead of print (7 cases) [REVIEW]
(2017): Collins M+, Ann Oncol 28(11), 2860
(2016): Spain L+, Cancer Treat Rev 44, 51 [REVIEW]

Diarrhea

(2024): Zoghbi M+, Support Care Cancer 32(10), 680 [REVIEW]
(2019): Abu-Sbeih H+, Curr Opin Gastroenterol Oct, Epub ahead of print [REVIEW]
(2019): Yanai S+, Dig Endosc Oct, Epub ahead of print (11 cases) [REVIEW]
(2017): Collins M+, Ann Oncol 28(11), 2860
(2017): Gauci ML+, Cancer Immunol Immunother 66(11), 1399 [REVIEW]
(2016): Spain L+, Cancer Treat Rev 44, 51 [REVIEW]

Enterocolitis

(2020): Collins M+, Clin Gastroenterol Hepatol Jan, Epub ahead of print [REVIEW]
(2020): Hayashi Y+, Dig Dis Sci Jul, Online ahead of print (8 cases)

Enteropathy

(2019): Alsaadi D+, J Immunother Cancer 7(1), 203 (1 case)

Gastritis / pangastritis / gastric irritation

(2022): Sugiyama Y+, Endosc Int Open 10(7), E982-E989 (4 cases)
(2020): Fujii M+, Clin J Gastroenterol Sep, Online ahead of print (1 case / male) (with chemotherapy)

Gastrointestinal adverse reaction

(2024): Chornenkyy Y+, J Clin Pathol Sep, Online ahead of print
(2023): Cheng Y+, Front Immunol Jun (e-Collection) [REVIEW]
(2023): Zhang P+, Therap Adv Gastroenterol Apr (e-Collection) [REVIEW]
(2021): Macovei Oprescu A+, Cureus 13(11), e19945 [REVIEW]

Gastrointestinal bleeding

(2023): Mebarki S+, Bull Cancer Mar, Online ahead of print2%

Gastrointestinal disorder / discomfort

(2020): Sanz-Segura P+, Gastroenterol Hepatol (Spanish) Nov, Online ahead of print13%

Gastrointestinal perforation / perforated colon / gastric perforation

(2020): Meserve J+, Aliment Pharmacol Ther Dec, Online ahead of print<5% [REVIEW]

Hepatic (liver) disorder / hepatobiliary disorder / hepatic (liver) dysfunction

(2023): Yamada T+, Int J Clin Pharm Jan, Online ahead of print (with acetaminophen)

Hepatitis

(2022): Farshidpour M+, Middle East J Dig Dis 14(2), 244-253 [REVIEW]
(2022): Liu Z+, Front Pharmacol Jan (e-Collection) [REVIEW]
(2022): Miah A+, J Cancer Res Clin Oncol Sep, Online ahead of print6%
(2021): Biewenga M+, Hepatol Int Feb, Online ahead of print2% (grade 3–4)
(2020): Gauci ML+, Clin Res Hepatol Gastroenterol Aug, Online ahead of print6% (≥ grade 3)
(2019): Chen C+, Oncoimmunology 8(5), e1581547 (≥ grade 3) [REVIEW]
(2017): Gauci ML+, Cancer Immunol Immunother 66(11), 1399 [REVIEW]
(2016): Spain L+, Cancer Treat Rev 44, 51 [REVIEW]

Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)

(2025): Yamamoto T+, Hepatol Res May, Online ahead of print (≥ grade 3 / 80 cases)
(2024): Ito T+, Hepatol Res Jun, Online ahead of print [REVIEW]
(2024): Jiang Y+, Curr Oncol 31(11), 7129-714314% (7% ≥ grade 3) [REVIEW]
(2024): Kawano M+, Diagnostics (Basel) 14(8), 815
(2024): Yue M+, Int Immunopharmacol Mar, Online ahead of print [REVIEW]
(2023): Atallah E+, JHEP Rep Oct (e-Collection) 9% (associated with combination therapy)
(2023): Gudd CLC+, Semin Liver Dis 43(4), 402-417 [REVIEW]
(2023): Hountondji L+, JHEP Rep Jun (e-Collection) (117 cases)
(2023): Kobayashi T+, J Clin Transl Hepatol 11(5), 1239-1245 [REVIEW]
(2022): Taherian M+, J Clin Transl Pathol 2(3), 83-90 [REVIEW]
(2021): Ito T+, Hepatol Int Aug, Online ahead of print5% (≥ grade 3)
(2020): Yamamoto A+, J Cancer Res Clin Oncol Nov, Online ahead of print
(2017): Cramer P+, Curr Gastroenterol Rep 19(1), 3 [REVIEW]

Liver dysfunction

(2020): Sanz-Segura P+, Gastroenterol Hepatol (Spanish) Nov, Online ahead of print3%
(2019): Zen Y+, Semin Diagn Pathol Jul, Epub ahead of print [REVIEW]

Liver injury

(2020): Mizuno K+, J Gastroenterol Mar, Epub ahead of print5% (≥ grade 3)
(2019): Imoto K+, Can J Gastroenterol Hepatol Dec (e-Collection) 15% (all-grade)

Nausea

(2017): Collins M+, Ann Oncol 28(11), 2860

Pancreatic injury

(2020): Porcu M+, Target Oncol Jan, Epub ahead of print [REVIEW]

Pancreatitis / acute pancreatitis

(2025): Fang W+, Front Pharmacol Mar (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Zhan M+, Expert Opin Drug Saf Apr, Online ahead of print1%
(2023): Shirwaikar Thomas A+, Curr Gastroenterol Rep Oct, Online ahead of print [REVIEW]
(2022): Sayed Ahmed A+, Curr Opin Gastroenterol Jul, Online ahead of print [REVIEW]

Sclerosing cholangitis

(2025): Yasuda T+, Dig Liver Dis Jan (5 cases)
(2023): Yamamoto T+, Invest New Drugs May, Online ahead of print (8 cases)
(2020): Onoyama T+, World J Gastroenterol 26(3), 353-365 [REVIEW]

Vomiting

(2017): Collins M+, Ann Oncol 28(11), 2860

Cystitis (includes interstitial cystitis / bladder pain syndrome)

(2022): Li J+, Front Immunol Jan (e-Collection) [REVIEW]

Ureteritis

(2022): Li J+, Front Immunol Jan (e-Collection) [REVIEW]

Anemia

(2020): Tian Z+, Cancer Manag Res 12, 133919% (grade 3/4) (with doxorubicin)

Aplastic anemia

(2023): Guo Q+, Front Pharmacol Jan (e-Collection) (13 cases) [REVIEW] (case study analysis)

Eosinophilia / eosinophils increased

(2025): Diamantopoulos PT+, Cancer Med 14 (7), e7067921%
(2025): Lyu L+, Int J Cancer Mar, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2022): Takayasu S+, Sci Rep 12(1), 1294 (association)
(2020): Scanvion Q+, Oncoimmunology 9(1) (e-Collection) (37 cases)

Hematological adverse effect

(2020): Omar NE+, Front Immunol 11, 1354 [REVIEW]
(2019): Davis EJ+, Oncologist 24(5), 584-588 [REVIEW]
(2019): Delanoy N+, Lancet Haematol 6(1), e48

Hemophagocytic lymphohistiocytosis

(2019): Noseda R+, J Immunother Cancer 7(1), 117 (34 cases) [REVIEW]

Hemophilia

(2022): Moore DC+, Haemophilia Jul, Online ahead of print (12 reports) (association)

Neutropenia (neutrophils decreased)

(2019): Zhou H+, Front Pharmacol 10, e3875% (≥ grade 3) [REVIEW]

Pancytopenia (includes bicytopenia)

(2019): Cybulska-Stopa B+, Case Rep Oncol 12(3), 820 (1 case)

Platelets decreased

(2019): Zhou H+, Front Pharmacol 10, e38714% [REVIEW]

Pure red cell aplasia

(2022): Guo Q+, Int Immunopharmacol Nov, Online ahead of print (55 cases) [REVIEW]

Thrombocytopenia / platelets decreased

(2024): Moore DC+, Int Immunopharmacol Feb, Online ahead of print (pharmacovigilance)
(2020): Liu X+, Front Oncol Dec (e-Collection) [REVIEW]

Arthralgia

(2023): Mebarki S+, Bull Cancer Mar, Online ahead of print7%
(2022): Maeda A+, Rheumatology (Oxford) Sep, Online ahead of print14%

Arthritis / polyarthritis

(2024): Springer R+, Immunotherapy Jan, Online ahead of print

Asthenia / fatigue

(2019): Chen C+, Oncoimmunology 8(5), e1581547 (≥ grade 3) [REVIEW]
(2019): Wang BC+, Cancer Med Aug, Epub ahead of print15% (≥ grade 3) [REVIEW]
(2019): Zhou H+, Front Pharmacol 10, e38715% [REVIEW]

Inflammatory arthritis

(2025): Yoon JS+, Intern Med J Jan, Online ahead of print (20 cases)
(2024): Ghosh N+, Rheum Dis Clin North Am 50(2), 325-335 [REVIEW]
(2024): Gómez-Puerta JA+, Rheum Dis Clin North Am 50(2), 161-179 [REVIEW]
(2024): Rose N+, Eur J Rheumatol Jan, Online ahead of print [REVIEW]
(2024): Singh N+, Rheum Dis Clin North Am 50(2), 269-279 [REVIEW]
(2022): Chan KK+, J Inflamm Res May (e-Collection) [REVIEW]
(2022): Gómez-Puerta JA+, Front Med (Lausanne) Jun (e-Collection)
(2022): Ghosh N+, Semin Arthritis Rheum Oct, Online ahead of print
(2022): Jensen AK+, Biomed Pharmacother Feb, Online ahead of print [REVIEW]
(2022): Kim ST+, Nat Commun 13(1), 1970 (20 cases)
(2020): Angelopoulou F+, Rheumatol Int Aug, Online ahead of print58% [REVIEW]
(2019): Braaten TJ+, Ann Rheum Dis Sep, Epub ahead of print

Musculoskeletal adverse effects

(2023): Liu H+, Front Pharmacol Oct (e-Collection) (FDA Adverse Event Reporting System data)

Myalgia/Myositis/Myopathy/Myotoxicity

(2024): Jayan A+, Rheum Dis Clin North Am 50(2), 281-290 [REVIEW]
(2022): Longinow J+, Cancer Med Sep, Online ahead of print (11 cases) (with myasthenia gravis, myositis and myocarditis overlap syndrome)
(2021): Pathak R+, Oncologist Aug, Online ahead of print [REVIEW]
(2020): Angelopoulou F+, Rheumatol Int Aug, Online ahead of print14% [REVIEW]

Myasthenia gravis

(2023): Masi G+, Ann Clin Transl Neurol Mar, Online ahead of print (5 cases)
(2022): Longinow J+, Cancer Med Sep, Online ahead of print (11 cases) (with myasthenia gravis, myositis and myocarditis overlap syndrome)
(2022): Marco C+, J Clin Med 12(1), 130 (6 cases)
(2022): Niimura T+, J Clin Pharmacol Dec, Online ahead of print (age association)
(2021): Ogawa K+, Clin Drug Investig Jun, Online ahead of print [REVIEW]
(2021): Pathak R+, Oncologist Aug, Online ahead of print [REVIEW]
(2020): Huang YT+, Front Neurol 11, 634 [REVIEW] (immune-related)
(2020): Yao S+, Zhongguo Fei Ai Za Zhi (Chinese) Aug, Online ahead of print [REVIEW]
(2019): Becquart O+, J Immunother Jun, Epub ahead of print [REVIEW]
(2019): Lara MS+, Clin Lung Cancer Apr, Epub ahead of print (1 case)

Myofasciitis

(2020): Daoussis D+, Rheumatology (Oxford) 59(5), 1041

Polymyalgia rheumatica

(2024): Hysa E+, Autoimmun Rev Aug, Online ahead of print [REVIEW]
(2024): Liew DFL+, Rheum Dis Clin North Am 50(2), 255-267 [REVIEW]
(2022): Ghosh N+, Semin Arthritis Rheum Oct, Online ahead of print
(2020): Angelopoulou F+, Rheumatol Int Aug, Online ahead of print12% [REVIEW]

Psoriatic arthralgia / psoriatic arthritis

(2020): Nigro O+, Immunotherapy Apr, Epub ahead of print (1 case)

Keratoconjunctivitis

(2021): Urasaki T+, Immunotherapy Nov, Online ahead of print (2 cases)

Ocular adverse effect

(2020): Bomze D+, Ocul Immunol Inflamm Aug, Online ahead of print [REVIEW]
(2019): Fang T+, J Curr Ophthalmol 31(3), 319 [REVIEW]

Ocular inflammation

(2022): Chaudot F+, J Clin Med 11(17), 4993 [REVIEW]

Ocular myasthenia gravis

(2025): Dezard VA+, J Neuroophthalmol Apr, Online ahead of print (3 cases) [REVIEW]

Uveitis / anterior uveitis / posterior uveitis / panuveitis

(2025): Ide N+, Anticancer Res 45(5), 2215-2223 (pharmacovigilance / pharmacoepidemiology)
(2023): Thibault T+, Ophthalmology Oct, Online ahead of print (46 cases) (association)
(2021): Dow ER+, Ocul Immunol Inflamm 29(1), 203-211 [REVIEW]

Ototoxicity

(2020): Hu F+, Immunotherapy May, Online ahead of print [REVIEW] (class-specific ear toxicities detected)
(2019): Lemasson J+, Eur J Cancer 117, 116 (4 cases)

Vestibular disorder / vestibulopathy

(2020): Koch EAT+, J Immunother Dec, Online ahead of print (1 case / male)

Fanconi syndrome (proximal tubular dysfunction)

(2020): Farid S+, Cureus 12(4), e7686 (1 case)

Nephritis / interstitial nephritis / tubulointerstitial nephritis

(2024): Elghawy O+, J Oncol Pharm Pract May, Online ahead of print (12 cases)
(2022): Abudayyeh A+, Cancers (Basel) 14(21), 5267 (35 cases)
(2021): Draibe JB+, Clin Kidney J 14(3), 884-890 (13 cases)

Nephropathy

(2021): Gérard AO+, Cancer Immunol Immunother Jun, Online ahead of print (63 cases)

Nephrotoxicity / kidney injury / acute kidney injury (AKI) / drug-induced kidney injury

(2025): Ding Z+, Am J Cancer Res 15(4), 1480-1493 [REVIEW]
(2024): Thomas AS+, Gastro Hep Adv 3(3), 361-367 (229 cases)
(2023): Seethapathy H+, Immunol Rev Jul, Online ahead of print [REVIEW]
(2022): Catalano M+, Front Med (Lausanne) Dec (e-Collection) [REVIEW]
(2022): Gérard AO+, Clin Kidney J 15(10), 1881-1887 (suggested association with administration of fluindione, a non-steroidal anti-inflammatory drug, or a proton-pump inhibitor)
(2022): Lv D+, Discov Med 33(170), 137-141 [REVIEW]
(2022): Tian R+, Kidney Dis (Basel) 8(3), 190-201 [REVIEW]
(2022): Verploegen MFA+, Kidney360 3(3), 524-529 (16 cases)
(2020): Tinawi M+, Cureus 12(12), e12204 [REVIEW]

Interstitial lung disease / interstitial pneumonitis / interstitial pneumonia (cryptogenic organizing pneumonia) / drug-induced interstitial lung disease

(2025): Kanaji N+, J Pers Med 15(3), 11518% (fatal / 6 cases)
(2025): Nakai S+, Respir Investig 63(3), 259-26410%
(2024): Utsunomiya A+, Expert Opin Drug Saf Dec, Online ahead of print
(2024): Yokoi M+, J Pharm Health Care Sci 10(1), 526%
(2022): Camard M+, Respir Med Res Nov, Online ahead of print
(2019): Nakanishi Y+, Respir Investig Jun, Epub ahead of print17% (pre-existing lung abnormalities a risk factor)

Pneumonia

(2017): Delaunay M+, Eur Respir J 50(2), Epub23%

Pneumonitis

(2024): Matsukane R+, J Immunother Cancer 12(12), e01011410–20%
(2023): Allen E+, Front Oncol Oct (e-Collection) (10 cases) (association with patients with pre-existing obstructive pulmonary disease)
(2022): Yin J+, Front Immunol Apr (e-Collection) 3–5% [REVIEW] (non-small-cell lung cancer patients)
(2021): Abraham G+, Int J Cancer Nov, Online ahead of print4%
(2021): Naganuma K+, Chemotherapy Apr, Online ahead of print (grade 3 / 1 case)
(2021): Sun Z+, Invest New Drugs Jan, Online ahead of print (19 cases)
(2020): Sakamoto K+, Respir Investig Jul, Online ahead of print [REVIEW]
(2020): Tian S+, Int J Radiat Oncol Biol Phys Jan, Epub ahead of print11% (grade 3) (with stereotactic body radiotherapy )
(2020): Tian Z+, Cancer Manag Res 12, 133910% (with doxorubicin)
(2020): Zhu S+, Front Oncol 10, 17853% [REVIEW]
(2019): Chen C+, Oncoimmunology 8(5), e1581547 (≥ grade 3) [REVIEW]
(2019): Zhou H+, Front Pharmacol 10, e3874% (≥ grade 3) [REVIEW]
(2017): Delaunay M+, Eur Respir J 50(2), Epub16%
(2017): Gauci ML+, Cancer Immunol Immunother 66(11), 1399 [REVIEW]
(2017): Khunger M+, Chest 152(2), 271 [REVIEW]
(2017): Zhang S+, Mol Cancer Ther 16(8), 1588 [REVIEW]
(2016): Nishino M+, JAMA Oncol 2(12), 1607 [REVIEW]
(2016): Tabchi S+, Curr Opin Oncol 28(4), 269 [REVIEW]

Pulmonary toxicity

(2024): Rolim I+, Virchows Arch Nov, Online ahead of print

Respiratory disorder

(2022): Cui C+, Front Oncol Aug (e-Collection) [REVIEW]
(2020): Mitropoulou G+, Respiration Jan, Epub ahead of print (severe / 2 cases)

Sinonasal disease

(2024): Pak KY+, Ann Otol Rhinol Laryngol Aug, Online ahead of print [REVIEW]

(2024): Tzoumpa S+, Immunotherapy Sep, Online ahead of print (12 cases)
(2017): Dein E+, J Immunother 40(8), 312-314

Adverse effects / adverse reactions

(2025): Alwhaibi A+, J Clin Med 14(2), 388
(2024): Miller S+, Lancet Oncol Nov, Online ahead of print
(2024): Tan K+, Clin Transl Oncol Jun, Online ahead of print [REVIEW]
(2024): Tyagi S+, Crit Rev Oncol Hematol May, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2023): Elmakaty I+, Cancer Cell Int 23(1), 90 [REVIEW]
(2023): Liao D+, Int Immunopharmacol Feb, Online ahead of print (with epidermal growth factor receptor (EGFR) / anaplastic lymphoma kinase (ALK) inhibitor)
(2022): Wen Y+, Expert Rev Hematol Aug, Online ahead of print [REVIEW]
(2022): Xu J+, Front Immunol Jan (e-Collection) [REVIEW] (with chemotherapy)
(2021): Al Nuhait M+, Sci Prog 104(1) (e-Collection) [REVIEW]
(2021): Paderi A+, Curr Oncol 28(5), 3259-3267 [REVIEW]
(2021): Pala L+, Expert Opin Drug Saf Sep, Online ahead of print [REVIEW]
(2021): Perdigoto AL+, Curr Opin Immunol 69, 29-38 [REVIEW]
(2021): Qi Y+, Front Pharmacol Jun (e-Collection) 64% (13% severe)
(2021): Tian Y+, Front Oncol May (e-Collection) [REVIEW]
(2020): Allouchery M+, J Immunother Cancer 8(2), e001622
(2020): Cutroneo PM+, Br J Clin Pharmacol Jun, Online ahead of print49% (serious) [REVIEW]
(2020): Hommes JW+, Front Oncol Feb (e-Collection) [REVIEW]
(2020): Wang BC+, Oral Oncol Mar, Epub ahead of print94% (20% ≥ grade 3) [REVIEW]
(2020): Yamaguchi O+, Cancer Chemother Pharmacol Mar, Epub ahead of print
(2019): Bjornhart B+, Acta Oncol May, Epub ahead of print24% (grade 3–5) (1 case grade 5)
(2019): Fox B+, Clin Transl Oncol Jun, Epub ahead of print [REVIEW] (with other prescription drugs)
(2019): Huang YF+, Front Oncol Oct (e-Collection) [REVIEW] (with chemotherapy)
(2019): Ni X+, Clin Res Hepatol Gastroenterol Jun, Epub ahead of print12% ≥ grade 3 [REVIEW]
(2019): Zhou H+, Front Pharmacol 10, e38774% (24% ≥ grade 3; fatal / 2 cases) [REVIEW]
(2017): Hu YB+, Transl Lung Cancer Res 6(Suppl 1), S8 [REVIEW]
(2017): Le Burel S+, Eur J Cancer 82, 34

Death

(2025): Kanaji N+, J Pers Med 15(3), 115 (6 cases)
(2023): Guo Q+, Front Pharmacol Jan (e-Collection) (7 cases ) [REVIEW] (case study analysis)
(2022): Jing X+, Immunotherapy Sep, Online ahead of print (4 cases)
(2019): Zhou H+, Front Pharmacol 10, e387 (2 cases) [REVIEW]
(2018): Wang DY+, JAMA Oncol 4(12), 1721-1728 [REVIEW]
(2016): Johnson DB+, N Engl J Med 375(18), 1749 (2 cases)

Generalized edema (includes anasarca)

(2023): Velev M+, Eur J Cancer Jan (e-Collection) (20 cases)

Immune-related adverse effect

(2025): Le J+, Hum Vaccin Immunother Feb (e-Collection) [REVIEW]
(2025): Sun Y+, Curr Opin Immunol Apr, Online ahead of print [REVIEW]
(2024): Guo AJ+, World J Clin Oncol 15(8), 1002-1020 [REVIEW]
(2024): Jayathilaka B+, Br J Cancer Nov, Online ahead of print [REVIEW]
(2024): Jayathilaka B+, Br J Cancer Dec, Online ahead of print (Correction)
(2024): Jayathilaka B+, Crit Rev Oncol Hematol Dec, Online ahead of print [REVIEW]
(2024): Pozzessere C+, Cancers (Basel) 16(14), 2585 [REVIEW]
(2024): Riveiro-Barciela M+, Gastroenterol Hepatol Jan, Online ahead of print [REVIEW]
(2023): Burnett DL+, Front Endocrinol (Lausanne) Oct (e-Collection) [REVIEW]
(2023): Geng R+, Front Immunol Mar (e-Collection)
(2023): Guérin C+, Bull Cancer May, Online ahead of print31% (≥ grade 2)
(2023): Lou S+, Front Pharmacol Apr (e-Collection) 39%
(2023): Velev M+, Eur J Cancer 179, 28-47
(2022): Jing X+, Immunotherapy Sep, Online ahead of print (fatal / 4 cases)
(2022): Storm BN+, J Geriatr Oncol Jun, Online ahead of print
(2021): Abdayem P+, Expert Opin Drug Saf Jan, Online ahead of print [REVIEW]
(2021): Husain B+, J Cancer Res Clin Oncol Apr, Online ahead of print
(2021): Qi Y+, Front Pharmacol Jun (e-Collection) 15%
(2021): Zhao Q+, Front Immunol Sep (e-Collection) [REVIEW]
(2021): Zhao Z+, Target Oncol May, Online ahead of print9% (? grade 3) (+/- chemotherapy)
(2020): Abou Alaiwi S+, J Immunother Cancer 8(1), e00014445%
(2020): Allenbach Y+, Autoimmun Rev Jun, Online ahead of print [REVIEW] (rheumatic and musculoskeletal Immune-related adverse effects)
(2020): Karimian Z+, BMC Cancer 20(1), 1128 [REVIEW]
(2020): Qin Q+, Zhongguo Fei Ai Za Zhi (Chinese) Aug, Online ahead of print [REVIEW]
(2020): Tang H+, Zhongguo Yi Xue Ke Xue Yuan Xue Bao (Chinese) 42(6), 825-830 [REVIEW] (biomarkers)
(2020): Triggianese P+, Autoimmun Rev Jun, 102590 [REVIEW]
(2019): Rambhia PH+, Int J Clin Oncol Jul, Epub ahead of print [REVIEW] (sarcoidosis-like granulomas)
(2019): Tison A+, Arthritis Rheumatol Aug, Epub ahead of print
(2019): Wei KZ+, Melanoma Manag 6(1), eCollection MMT1329%

Drugs belonging to restart save

class – Immune checkpoint inhibitor (incl. programmed death receptor-1 (PD-1) inhibitor) – 8 items found

Adverse reactions attributed to entire drug class 'Immune checkpoint inhibitor (incl. programmed death receptor-1 (PD-1) inhibitor)'

Litt's app available free to subscribers